Comparison of NEDA3 at one year between alemtuzumab and natalizumab in treatment-naive relapsing-remitting multiple sclerosis patients.

被引：0
|
作者：
Gomez, A. [1 ]
Rodriguez, F. [1 ]
Chico, J. L. [1 ]
Sanchez Sanchez, A. [1 ]
Natera, E. [1 ]
Sainz de la Maza, S. [1 ]
Villar Guimerans, L. M. [2 ]
Buisan Catevilla, F. J. [1 ]
Costa-Frossard Franca, L. [1 ]
Masjuan, J. [1 ]
Monreal, E. [1 ]
机构：
[1] Hosp Ramon & Cajal, Neurol, Madrid, Spain
[2] Hosp Univ Ramon y Cajal, Inmunol, Madrid, Spain
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2019年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO1245
引用
收藏
页码：493 / 493
页数：1
相关论文
共 50 条
  • [41] Alemtuzumab Improves Contrast Sensitivity in Relapsing-Remitting Multiple Sclerosis Patients
    Balcer, Laura
    Galetta, Steven
    Maguire, Maureen
    Palmer, Jeffrey
    Margolin, David
    Rizzo, Marco
    NEUROLOGY, 2011, 76 (09) : A446 - A446
  • [42] Effect of alemtuzumab on quality of life in patients with relapsing-remitting multiple sclerosis
    Bass, Ann
    MULTIPLE SCLEROSIS, 2009, 15 (11): : 1396 - 1396
  • [43] Subcutaneously delivered natalizumab for the treatment of highly active relapsing-remitting multiple sclerosis
    Haluskova, S.
    Valis, M.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2022, 85 (03) : 206 - 212
  • [44] Treatment with alemtuzumab after fingolimod in relapsing-remitting multiple sclerosis is effective and safe
    Alcala, C.
    Gascon, F.
    Perez-Miralles, F.
    Dominguez, J. A.
    Garcia Gil-Perotin, S.
    Casanova, B.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 274 - 274
  • [45] Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands
    Piena, M. A.
    Heisen, M.
    Wormhoudt, L. W.
    van Wingerden, J.
    Frequin, S. T. F. M.
    Uitdehaag, B. M. J.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (10) : 968 - 976
  • [46] Cerebral toxoplasmosis in patient with relapsing-remitting multiple sclerosis under treatment with alemtuzumab
    Raquel, Calle-Calle
    Lucia, Triguero-Cueva
    Carmen, Valderrama-Martin
    Ana, Romero-Villarrubia
    Antonio, Tapia-Gomez
    Juan, Pasquau-Liano
    Carmen, Arnal-Garcia
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 39
  • [47] Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia
    Algahtani, Hussein
    Shirah, Bader
    Abobaker, Hind
    Alghanaim, Nebras
    Kamel, Fatemah
    CLINICAL NEUROPHARMACOLOGY, 2018, 41 (06) : 199 - 201
  • [48] Eligibility to natalizumab treatment in relapsing-remitting multiple sclerosis patients in Emilia-Romagna, Italy
    Granella, F.
    Immovilli, P.
    Baldi, E.
    Montepietra, S.
    Tsantes, E.
    Senesi, C.
    Motti, L.
    Tola, M. R.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S204 - S204
  • [49] Natalizumab in the treatment of patients with relapsing-remitting multiple sclerosis: the preliminary results of the observational program "Sovet"
    Popova, E. V.
    Brylev, L. V.
    Davydovskaya, M. V.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2013, 113 (02) : 79 - +
  • [50] COST-UTILITY ANALYSIS OF ALEMTUZUMAB VERSUS NATALIZUMAB FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: US PAYER PERSPECTIVE
    Smith, A.
    Hashemi, L.
    Ma, I
    VALUE IN HEALTH, 2016, 19 (07) : A431 - A431
12345